This legislation mandates the Secretary of Veterans Affairs to make opioid overdose rescue medications , such as naloxone, readily available to eligible veterans and their caregivers. These medications are to be provided at no charge and without a prescription at Department of Veterans Affairs pharmacies. Recipients will also receive essential drug information regarding the proper use of these life-saving medications. To safeguard veteran privacy, the bill strictly limits the collection of personally identifiable information (PII) to only what is necessary for prescribing the medication. This PII may solely be used for delivering, evaluating, and enhancing healthcare quality, explicitly prohibiting its use to prevent employment or as evidence of drug use history or addiction. Furthermore, the Secretary is required to submit annual reports to Congress, beginning two years after implementation. These reports must include the number of recipients, assessments of expanding the program to immediate family members and non-Department healthcare providers, and trends in medication utilization, along with any other recommendations.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Veterans' Affairs.
Introduced in Senate
Read twice and referred to the Committee on Veterans' Affairs.
Armed Forces and National Security
End Veterans Overdose Act of 2026
USA119th CongressS-3758| Senate
| Updated: 2/2/2026
This legislation mandates the Secretary of Veterans Affairs to make opioid overdose rescue medications , such as naloxone, readily available to eligible veterans and their caregivers. These medications are to be provided at no charge and without a prescription at Department of Veterans Affairs pharmacies. Recipients will also receive essential drug information regarding the proper use of these life-saving medications. To safeguard veteran privacy, the bill strictly limits the collection of personally identifiable information (PII) to only what is necessary for prescribing the medication. This PII may solely be used for delivering, evaluating, and enhancing healthcare quality, explicitly prohibiting its use to prevent employment or as evidence of drug use history or addiction. Furthermore, the Secretary is required to submit annual reports to Congress, beginning two years after implementation. These reports must include the number of recipients, assessments of expanding the program to immediate family members and non-Department healthcare providers, and trends in medication utilization, along with any other recommendations.